EXECUTIVE DIRECTORS

Ms. LI, Kei Ling （李其玲女士）, is an Executive Director and the Chairman of the Company, and one of the founders of the Group. Ms. Li founded the Group in December 1995 and was appointed to the Board in October 2002. Ms. Li is also the Chairman of Dawnrays International Co. Ltd., Dawnrays International Co. Ltd.（東瑞國際股份有限公司）, Suzhou Dawnrays Pharmaceutical Co., Ltd., Su Zhou Dawnrays Pharmaceutical Science and Technology Co., Ltd., Dawnrays (Nantong) Pharmaceutical Science and Technology Co., Ltd. and Dawnrays Pharma (Hong Kong) Ltd., which are all subsidiaries of the Company. She is the Chairman of the Remuneration Committee and Nomination Committee. Ms. Li has over twenty years of experience in corporate management, strategic planning, business operations and finance, in particular for pharmaceutical enterprises in the PRC. She is responsible for supervising the strategic management decisions to ensure good corporate governance practices and business policies are established, and executing the overall developmental strategies of the Group.

Mr. HUNG, Yung Lai （熊融禮先生）, is an Executive Director of the Company and one of the founders of the Group. Mr. Hung founded the Group in December 1995 and was appointed to the Board in October 2002. Mr. Hung also holds directorship in Dawnrays International Co. Ltd., Dawnrays International Co. Ltd.（東瑞國際股份有限公司）, Suzhou Dawnrays Pharmaceutical Co., Ltd., Su Zhou Dawnrays Pharmaceutical Science and Technology Co., Ltd., Dawnrays (Nantong) Pharmaceutical Science and Technology Co., Ltd. and Dawnrays Pharma (Hong Kong) Ltd., which are all subsidiaries of the Company. Mr. Hung holds a degree from 上海音樂學院 (Shanghai Conservatory of Music). He has over twenty years of experience in corporate management and corporate development, and has participated in founding and managing of pharmaceutical and high-tech enterprises. Mr. Hung is an executive director and the chairman of Sing Lee Software (Group) Ltd., a company listed on the Growth Enterprise Market of the Stock Exchange of Hong Kong Ltd.

Mr. LI, Tung Ming （李東明先生）, is an Executive Director of the Company. Mr. Li joined the Group in April 2000 and was appointed to the Board in January 2004. Mr. Li also holds directorship in Suzhou Dawnrays Pharmaceutical Co., Ltd., Su Zhou Dawnrays Pharmaceutical Science and Technology Co., Ltd. and Dawnrays Pharma (Hong Kong) Ltd., which are all subsidiaries of the Company. Mr. Li is also the supervisor of Dawnrays (Nantong) Pharmaceutical Science and Technology Co., Ltd., a subsidiary of the Company. Mr. Li has over twenty years of experience in the pharmaceutical industry in the PRC, and began his career in product development, promotion, sales and corporate management in the pharmaceutical market in the PRC in 1980. Mr. Li is responsible for liaison with the Group’s academic network of medical experts and academic advisers and assists in new product development of the Group.

Mr. GAO, Yi （高毅先生）, is an Executive Director and the Chief Executive Officer of the Company. He joined the Group in July 2003 and was the executive vice president of the Group. Mr. Gao was appointed to the Board in January 2007. He also holds directorship in Suzhou Dawnrays Pharmaceutical Co., Ltd., Su Zhou Dawnrays Pharmaceutical Science and Technology Co., Ltd., Dawnrays (Nantong) Pharmaceutical Science and Technology Co., Ltd. and Dawnrays Pharma (Hong Kong) Ltd., which are all subsidiaries of the Company. Mr. Gao is responsible for the daily business operations and management of the Group. From 1994 to 2003, Mr. Gao was the deputy general manager and general manager of Hebei Union Pharmaceutical Co., Ltd. and Zhuhai Economic Zone Li Kang Pharmaceuticals Co., Ltd. respectively each for five years.

INDEPENDENT NON-EXECUTIVE DIRECTORS

Mr. PAN, Xue Tian （潘學田先生）, is an Independent Non-executive Director of the Company. Mr. Pan joined the Group in June 2003. He is a member of the Audit Committee, the Remuneration Committee and the Nomination Committee of the Company. Mr. Pan is the vice president of 中國醫院協會 (Chinese Hospital Association). Mr. Pan has extensive experience in drug administration and supervision, medical hygiene and hospital management, and has assumed various senior management positions in the Ministry of Health of the PRC. He graduated from the medicine faculty of 中國大連醫學院 (Dalian Medical University of the PRC).

Mr. CHOI, Tat Ying Jacky （蔡達英先生）, is an Independent Non-executive Director of the Company. Mr. Choi joined the Group in September 2004. He is the Chairman of the Audit Committee, a member of the Remuneration Committee and the Nomination Committee of the Company respectively. Mr. Choi has extensive experience in financial and treasury management, corporate finance, investment and audit. He earned his Bachelor degree of Business Administration from Hong Kong Baptist University with a first class honours in 1990. Mr. Choi is a practising member of the Hong Kong Institute of Certified Public Accountants and currently serving as the chief financial officer of Hong Kong Mercantile Exchange Ltd. and is an independent non-executive director of Norstar Founders Group Ltd., a company listed on the Main Board of the Stock Exchange of Hong Kong Ltd.

Mr. LO, Tung Sing Tony （勞同聲先生）, is an Independent Non-executive Director of the Company. Mr. Lo joined the Group in October 2010. He is a member of the Audit Committee, the Remuneration Committee and the Nomination Committee of the Company respectively. Mr. Lo has extensive experience in financial management and business development in Hong Kong and multinational companies. He obtained his Bachelor degree in Business Administration from The Chinese University of Hong Kong and Master of Science in Financial Management from the University of London. Mr. Lo is an associate member of the Hong Kong Institute of Certified Public Accountants and a full member of CPA Australia. He currently holds the position of financial controller (betting) at The Hong Kong Jockey Club.

NON-EXECUTIVE DIRECTOR

Mr. LEUNG, Hong Man （梁康民先生）, is a Non-executive Director of the Company. He joined the Group and was appointed to the Board in November 2005. Mr. Leung has started his business career in knitting machinery since 1993. He has over ten years’ experience in sales and management and also over ten years’ experience in finance and property investments. In recent years, Mr. Leung has strived to exploit business in hi-tech agriculture and arts and cultural industries. Mr. Leung currently is the shareholder and the director of Toyo International Investment Ltd., of which has been one of the substantial shareholders (as required to be disclosed under Part XV of the Securities and Futures Ordinance) of the Company since September 2005.

STRATEGIC ADVISER

Kehan XU, Ph.D., DBA （許克寒博士）, is a Strategic Adviser of the Company. He joined the Group in November 2003 and was an executive director and the finance director of the Company between March 2004 and March 2007. Dr. Xu advises the Company’s investor relations’ policies and other related tasks. Dr. Xu holds a Doctor of Philosophy in Management from the Mays Business School at the Texas A&M University, USA and a Master of Business Administration from the University of Miami, USA (Specialization in Investments). Dr. Xu also received a Doctor of Business Administration from the Hong Kong Polytechnic University.

ACADEMIC ADVISERS

Mr. ZHONG, Nan Shan （鍾南山先生）, was invited to join our Group as a Senior Academic Adviser in April 2004. He graduated from 北京大學醫學部 (Beijing Medical University), and pursued his studies in the Respiratory Medicine Unit of the Royal Infirmary, University of Edinburgh and the Department of Respiratory Medicine of the St. Bartholomew’s Hospital, University of London. He is currently the academician of the Department of Medicine of The Chinese Academy of Engineering, the president of Chinese Medical Association, the Professor of Medicine in Guangzhou Medical College, the president of Guangzhou Association of Science and Technology and the director of Guangzhou Institute of Respiratory Disease. Mr. Zhong has been a medical adviser of the World Health Organisation Advisory Panel since 2000. He has written 4 books and published over 120 papers in the last decade. After the battle of Severe Acute Respiratory Syndrome (“SARS”), he was invited to be the lecturer in the annual meeting of American Thoracic Society – “Management of SARS in China” in Seattle, USA.

Mr. MEI, Hua （梅驊先生）, was invited to join our Group as a Senior Academic Adviser in April 2004. He graduated from 廣州華南醫學院 (Guangzhou South China Medical College) and was qualified as the specialist in urology from 北京醫學院附屬第一醫院 (The First Affiliated Hospital of Beijing Medical University) and Massachusetts General Hospital, USA. He has been the adviser and professor of 中山大學附屬第一醫院泌尿外科 (Department of Urology of The First Affiliated Hospital of Sun Yat-sen University) since 1980 and the director of 深圳中山泌尿外科醫院 (Department of Urology of Shenzhen Sun Yat-sen Hospital) since 1986. Since 1991, he has been the adviser for doctoral candidates in The First Affiliated Hospital of Sun Yat-sen University, the committee vice president of 中華醫學會泌尿外科學會 (The Urological Society of Chinese Medical Association) and the committee member of Urological Association of Asia and American Urological Association. Mr. Mei has also written 3 books about urology and surgery.

Ms. LIU, Li Sheng （劉力生女士）, was invited to join our Group as a Senior Academic Adviser in May 2005. She obtained a Bachelor degree of Science in Biology from Yenching University, Beijing in 1950, and a Doctor of Medicine from Peking Union Medical College, Beijing in 1954. From 1980 to 1981, she pursued her postdoctoral research in the Cardiovascular Research and Training Centre, University of Alabama at Birmingham. She is currently the Professor of Medicine in Fu Wai Hospital, Chinese Academy of Medical Sciences in Beijing, the director of Clinical Trials and Research Centre, Chinese Hypertension League in Beijing, the vice director of the National Center for Cardiovascular Disease Control and Research in China and the president of Asian Pacific Society of Hypertension. She has been the president and the honorary president of the Chinese Society of Cardiology since 1988 and the president of the Chinese Hypertension League since 1989. Ms. Liu has also been the vice president of the World Hypertension League and the co-chairperson of the Scientific Steering Committee of Global Health Forum Cardiovascular Disease in Developing Countries, World Health Organization since 1999. In 2006, Ms. Liu has been elected to be the president of the World Hypertension League. She is also the chief editor of the Chinese Journal of Hypertension and the members of a number of editorial boards of journals in cardiology and hypertension.

SENIOR MANAGEMENT

Mr. QIAO, Xiao Guang（喬曉光先生）, is the Executive Vice President of the Company, responsible for assisting the Chief Executive Officer to manage  production system & technology, research and development, infrastructure construction and equipment renovation of the Group. Mr. Qiao graduated from Siping Normal College (now known as Jilin Normal University) and Jilin University. He holds a Master degree in organic synthetic chemistry from Jilin University where he has taught for ten years. Mr. Qiao has over twelve years’ experience in production technology and management, production facilities maintenance and operations for pharmaceutical enterprises. Mr. Qiao joined the Group in June 2011.

Mr. ZHU, Qin Sheng （朱琴生先生）, is the Vice President of the Company, responsible for assisting the Chief Executive Officer in th easpects of Nantong project, administrative management, human resources, logistic management, safety and environmental protection. Mr. Zhu has over twenty-five years’ experience in production management, financial management and operations for pharmaceutical enterprises. He was the deputy factory director of 蘇州第三製藥廠 (Suzhou Third Pharmaceutical Factory) before joining the Group in April 1998.

Mr. LAM, Kam Wah （林錦華先生）, is the Vice President of the Company. Mr. Lam also holds directorship in Suzhou Dawnrays Pharmaceutical Co., Ltd., Su Zhou Dawnrays Pharmaceutical Science and Technology Co., Ltd. and Dawnrays Pharma (Hong Kong) Ltd., which are all subsidiaries of the Company. He graduated from The Chinese University of Hong Kong with a Bachelor degree in Social Sciences. Mr. Lam joined the Group in December 1995 and he has over fifteen years of experience in pharmaceutical trading and corporate management. Mr. Lam is involved in managing the Group’s international trade and daily administration of the Company.

Mr. BO, Hui （薄輝先生）, is the Vice President of the Company and the Head of Sales and Marketing of the Group. Mr. Bo graduated from the School of Pharmacy of Shengyang Pharmaceutical University with a Bachelor degree in Pharmacy and completed the study of the Postgraduate program in Enterprise Management from the School of Business of Sun Yat-sen University. Mr. Bo specializes in pharmacology and has accumulated over twenty years’ experience in pharmaceutical sales, marketing and business development. Mr. Bo was the general manager of Livzon Pharmaceutical Sales Company and the deputy head of sales and marketing of Livzon Pharmaceutical Group Inc. Mr. Bo joined the Group in August 2004.
　

Mr. SU, GuoQiang(蘇國強先生), is the Vice President of the Company and the General Manager of Suzhou Dawnrays Pharmaceutical Co., Ltd., responsible for assisting the Chief Executive Officer to manage quality assurance and GMP compliance and also the overall operations of Suzhou Dawnrays Pharmaceutical Co., Ltd. Mr. Su graduated from 武漢化工學院 (Wuhan Institute of Chemical Technology) in chemical pharmaceutical profession and is a qualifiedpharmaceutical engineer. He was the head of the research centre and the chief engineer of 蘇州第二製藥廠(Suzhou Second Pharmaceutical Factory). He joined the Group in November 2001.

Ms. WU, Ji Hong （吳繼紅女士）, is the Financial Controller of the Group and the General Manager of Guangdong Dawnrays Pharmaceutical Co., Ltd. Ms. Wu is responsible for legal affairs in China and the Group’s financial management including financial planning, capital budgeting, execution of costing, overall budget management and monitoring. Ms. Wu obtained a Bachelor degree of Science from The Economics and Commercial Institution of Center-South University with major in Economics and attained senior accountant qualification in the PRC. She achieved her MBA degree (EMBA focus) from Fudan University in June 2010. Ms. Wu has over fifteen years’ experience in auditing, budgeting, financial management, corporate banking, taxation, PRC’s taxation regulations and company law. Ms. Wu joined the Group in July 2003.

Mr. CHEN, Jian Dong （陳建東先生）, is the Head of Research and Development of the Group. Mr. Chen is a qualified pharmaceutical engineer and licensed pharmacist and has a Bachelor degree in Chemical Pharmacology from 中國藥科大學 (The Pharmaceuticals University of the PRC) where he spent three years as an assistant teacher. He was the head of the research centre and antibiotics workshop manager at 蘇州第四製藥廠 (Suzhou Fourth Pharmaceutical Factory) and the head of the registration section of the research and development department of 蘇州中化藥品工業有限公司 (Suzhou Chung-Hwa Chemical and Pharmaceutical Industrial Co., Ltd.) before joining the Group in April 2002.

Mr. LI, Jian Xiang （李建翔先生）, is the General Manager of Su Zhou Dawnrays Pharmaceutical Science and Technology Co., Ltd., responsible for the overall operations of Su Zhou Dawnrays Pharmaceutical Science and Technology Co., Ltd. Mr. Li has over twenty-five years’ experience in production management, engine facilities maintenance and operations for pharmaceutical enterprises. He was the factory director of 蘇州第二製藥廠 (Suzhou Second Pharmaceutical Factory) before joining the Group in April 1998.